1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotecan and oxaliplatin ...
Key points:1. TriNetX is using real world data to reduce clinical trial enrollment time by as much as 40 percent2. ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
1. In patients with a pancreatic or periampullary tumour undergoing pancreaticoduodenectomy (PD), this retrospective study found no difference in surgical ...
1. Polycystic ovarian syndrome (PCOS) diagnosis puts women at 1.9 times higher risk of pancreatic cancer 2. PCOS was an ...
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
1. Median disease-free survival is longer in patients receiving mFOLFIRINOX as compared to those receiving gemcitabine. 2. Median overall survival ...
1. The use of a neoadjuvant gemcitabine-based chemoradiotherapy before surgery and adjuvant gemcitabine increased the overall survival rate when compared ...
